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Abstract
Background:  Explicit criteria for determining potentially inappropriate medication consumption in elderly were
elaborated by Beers et al. These lists have been used worldwide to evaluate medical prescriptions but there is little
epidemiologic evidence demonstrating negative consequences of inappropriate medication use. It has been reported that
some drugs could increase the risk of falls, which are a frequent and serious problem in elderly population. We aimed
to evaluate the association between the use of potentially inappropriate medications and the risk of falls.
Methods: The 3C Study is a multicentre prospective cohort study conducted in France with 4 years of follow-up. Non-
institutionalized men and women aged 65 years or over (N = 6343) were randomly selected from electoral rolls. Data
on socio-demographic, medical characteristics and medication use (based on self-reports and data from the national
healthcare insurance) were collected. Use of inappropriate medication for elderly was defined from established criteria.
Data about falls were collected at the two follow-up examinations (2 years and 4 years after baseline). The association
between the exposure to inappropriate medications and the risk of falls was evaluated using multivariate models (Cox
model and logistic regression).
Results:  32% of subjects reported inappropriate medication use at baseline and 29% at least two of the three
examinations; 22% had fallen 2 times or more during follow-up. Overall, inappropriate medication users had an increased
risk of falling. This increase was mainly due to the use of long-acting benzodiazepines (adjusted odds ratio (OR) = 1.4,
95% confidence interval: [1.1–1.8], in both occasional and regular users), other inappropriate psychotropics (adjusted OR
= 1.7 [1.7–2.7] in regular users), or medication with anticholinergic properties (adjusted OR = 1.6 [1.2–2.1] in regular
users). Neither occasional, nor regular use of short- or intermediate-acting benzodiazepines was associated with an
increased risk of falling. Further analysis in long-acting benzodiazepines users did not show any dose-effect relation
between the number of prescriptions filled over a 3-year period and the risk of falling.
Conclusion: Our study showed that use of inappropriate medications was associated with an increased risk of falling in
elderly persons. This increase was mainly due to long-acting benzodiazepines and other inappropriate psychotropics, and
to medications with anticholinergic properties.
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Background
In the United States, more than one-third of all medica-
tions is consumed by persons aged 65 years and over,
although they only represent approximately 15% of the
total population [1]. Similar data have been reported in
other developed countries. Due to concurrent prescription
of several drugs, the risk of inappropriate drug combina-
tions is increased in older persons [2,3]. Moreover, medi-
cation metabolism is affected by aging-related
pharmacokinetic and pharmacodynamic changes which
increase both drug half-life and drug free fraction. Lastly,
coexisting illnesses can interact with medications. For all
these reasons, older persons are at higher risk of experi-
encing adverse drug effects. To reduce frequency and
severity of these events is a current challenge for public
health agencies.
Beers et al [4] have elaborated explicit criteria for deter-
mining potentially inappropriate medication consump-
tion in older adults, using Delphi methods for obtaining
a consensus of recognized experts. The Beers list, which
initially defined inappropriate medication use in nursing
home residents, was afterwards modified and updated for
being used in general elderly populations [5-8]. The lists
identified specific drugs or drug prescriptions (excessive
dose, excessive treatment duration, inappropriate drug
combination and coexisting illness) with unfavorable
benefit/risk ratio or questionable efficacy. Inappropriate
medication lists have been used worldwide for evaluation
of medical prescriptions [9-13] but there has been little
evidence from epidemiological studies regarding the neg-
ative consequences of inappropriate medication use [14-
17].
Previous studies have suggested that some drugs could
increase the risk of falls, which are a frequent and serious
problem in elderly population [18-24]. In a one-year fol-
low-up study of persons aged 75 years and over living in
the community, about one-third reported at least one fall
[25]; higher annual risk of falls, up to 50%, were reported
in the oldest old or in persons living in nursing homes.
The consequences of injuries and fractures due to falls
(mortality, hospitalizations, disability, and institutionali-
zation) increase with age. In 2001, the American and Brit-
ish 'Guidelines for the prevention of falls in older persons'
therefore recommended careful review of medications
taken by elderly persons [26].
The aim of this prospective study was to evaluate the asso-
ciation between the use of potentially inappropriate med-
ications and the risk of falls in a large population-based
cohort of elderly persons.
Methods
Study population
The 3C Study is a multicentre prospective cohort study
conducted in France. Its primary objective is to evaluate
the relationship between vascular factors and dementia.
The detailed study protocol has already been reported
elsewhere [27]. Briefly, non-institutionalized men and
women aged 65 years or over were randomly selected
from electoral rolls of three French cities. The acceptance
rate was 37%. A total of 9294 people were included in the
study (4931 from Dijon, 2104 from Bordeaux and 2259
from Montpellier). The present study uses data collected
at baseline (1999–2000) and at the 2-year (2001–2002)
and 4-year (2003–2004) follow-up examinations.
The study protocol was approved by the Ethical Commit-
tee of the University hospital of Kremlin-Bicêtre. Each par-
ticipant signed legal consent forms.
General data
Data were collected by trained nurses and psychologists
during face-to-face interviews, using standardized ques-
tionnaires. For the purpose of the present study, the fol-
lowing baseline variables have been selected: socio-
demographic characteristics (gender, age, educational
level, living alone), past medical history, global cognitive
performance, depressive symptoms, diurnal drowsiness,
impaired mobility and body mass index (computed from
height and weight measurements). The Mini Mental State
Examination (MMSE) score, ranging from 0 to 30 (best
score), was used as a measure of global cognitive function-
ing. Depressive symptoms were evaluated with the Centre
for Epidemiologic Studies-Depression scale (CES-D). It
consists of 20 self-report items about the frequency of
depressive symptoms over the last week. Impaired mobil-
ity was assessed by three items of the Rosow and Breslau
scale: doing heavy housework, walking half a mile and
going up and down to the second floor [28,29]. Diurnal
drowsiness was assessed in a questionnaire about sleep
disorders.
Measurement of exposure to potentially inappropriate 
medications
At baseline and follow-up examinations, the question-
naire included an inventory of all drugs used during the
preceding month. To reduce underreporting, participants
were asked to provide medical prescriptions, drug pack-
ages and any other relevant material. The names of the
drugs were systematically coded using the Anatomical
Therapeutic Chemical (ATC) classification system [30].
No data on dose, duration of treatment or reason of pre-
scribing were collected. To cover the whole study period
(1999–2004) and to take into account changes in drug
marketing (new drugs and removals), we combined dif-
ferent lists of inappropriate medication [31,32]. Due toBMC Geriatrics 2009, 9:30 http://www.biomedcentral.com/1471-2318/9/30
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lack of information in the 3C study, criteria based on
dose, treatment duration and reason for prescribing could
not be considered.
The full list of criteria used to define inappropriate pre-
scription is given in Table 1 (see Additional file 1). As the
questionable efficacy of cerebral vasodilators was the
main reason for considering these medications as inap-
propriate, we also used a list of inappropriate medications
without this item. In addition, we built composite criteria
combining several individual criteria to investigate further
the impact of potentially inappropriate psychotropic
drugs (anticholinergic antidepressants, antipsychotic
drugs and anticholinergic hypnotic drugs) and potentially
inappropriate medication with anticholinergic properties.
Use of short- or intermediate-acting benzodiazepines in
older persons is considered as inappropriate when dosage
exceeds half the dose given to younger subjects. As infor-
mation about dosage was not available, we could not
identify inappropriate use of these drugs and we assumed
conservatively that subjects under short- or intermediate-
acting benzodiazepines took the appropriate dose.
Exposure to inappropriate medication was measured in
two ways. The first exposure measurement was only based
on baseline data. We created a binary variable to define
the overall exposure to at least one of the criteria listed in
table 1 and a series of binary variables for examining the
exposure to each individual criterion. Then, using data
collected at both baseline and the two follow-up examina-
tions, exposure to inappropriate medication was catego-
rized as: never user of any inappropriate medication
(reference group), user of inappropriate medication (any
or individual item) at one examination (occasional user)
and user at two or three examinations (regular user). The
total number of other drugs used (i.e. excluding inappro-
priate medication) was also computed.
About half of the 3C study participants were affiliated to
the French national healthcare insurance for active or
retired salaried workers (Caisse Nationale d'Assurance
Maladie des Travailleurs Salariés (CNAM-TS)). For these
persons, we obtained from the CNAM-TS individual data
about all drugs prescribed between 2001 and 2003. In
France, psychotropic drugs cannot be obtained without
medical prescription. The delivery of psychotropic medi-
cation to patients cannot exceed the quantity necessary for
one-month treatment, so patients under long-duration
treatment are required to buy medications monthly. We
used the healthcare insurance data for assessing further
psychotropic use. For both long-acting and short- or inter-
mediate-acting benzodiazepines, we computed the
number of boxes bought between 2001 and 2003, as reg-
istered in the CNAM database. This number was used as a
quantitative measure of the exposure. For further analysis,
this variable was categorized for comparing heavy users to
subjects with lower consumption of benzodiazepines
Falls
At baseline and at each follow-up examination, partici-
pants were asked about the occurrence of falls. No precise
definition of a fall was given to the participant before the
question being asked. The baseline question ("Did you
fall in the preceding months?") did not refer to a precise
number of months, while the follow-up question ("Did
you fall since the preceding examination?") covered a 2-
year period. Participants who reported to be fallen were
asked about the number of falls. Precise dates of falls were
not collected. The number of falls during follow-up (inci-
Table 1: List of Potentially Inappropriate Medications Used in the Present Study*
Criteria
Indomethacin Cimetidine
Phenylbutazone Stimulant laxatives
Concomitant use of 2 or more NSAIDs Long-acting sulfonylureas
Anticholinergic antidepressants Methocarbamol, baclofen, tetrazepam
Antipsychotic drugs Cerebral vasodilators (dihydroergocristine, ginkgo-biloba, pentoxifylline, ...)
Anticholinergic hypnotic drugs Meprobamate
Anticholinergic antihistamines Gastrointestinal antispasmodic drugs with anticholinergic properties
Anticholinergic muscle relaxants and antispasmodic drugs Antiemetics, cough suppressants, nasal decongestants, or antidrowsiness drugs with 
anticholinergic properties
Concomitant use of drugs with anticholinergic properties Dipyridamole
Long-acting benzodiazepines (half-life ≥ 20 h) Nitrofurantoin
Centrally acting antihypertensives Concomitant use of 2 or more psychotropic drugs from the same therapeutic class
Short-acting calcium-channel blockers Concomitant use of anticholinesterase drugs and drugs with anticholinergic properties
Reserpine Barbiturates (except phenobarbital)
Disopyramide Doxazosin
Ticlopidine
* According to the lists proposed by Beers [5], Fick [6] and Laroche [7].BMC Geriatrics 2009, 9:30 http://www.biomedcentral.com/1471-2318/9/30
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dent falls) was categorized as no fall, one fall, two or more
falls.
Data analysis
Among the initial 3C study population (9294 subjects),
2178 were excluded because they had diseases which
might affect gait and equilibrium (stroke (n = 291) and
Parkinson's disease (n = 73)), had fallen before baseline
evaluation (n = 1656), or both (n = 158). Of the remain-
ing 7116 subjects, further 773 subjects (10.9%) for whom
no data about falls had been collected during the follow-
up were also excluded. These subjects consumed more
inappropriate medication at baseline (37.9%, p < .001).
Our study population was finally composed of 6343 indi-
viduals.
The baseline characteristics of the study population were
categorized as follows. Education level was classified
according to the number of years of schooling: 5 years or
less, 6–9 years, 10–12 years and more than 12 years. The
body mass index was used as a three-category variable:
normal (< 25), excess weight (25–29), obesity (> 29). Par-
ticipants were classified as having impaired mobility if
they reported impairment for at least one of the three
items of the Rosow and Breslau scale. According to the
French validation of the CES-D scale, women scoring over
22 and men scoring over 16 were considered to have
depressive symptoms. Participants having a MMSE score
higher than 27 were considered to have good cognitive
functioning. After having excluded inappropriate medica-
tions, participants were categorized as using < 5 or ≥ 5
other drugs.
Associations between falls and the main characteristics of
the participants were assessed with chi-square tests (see
Additional file 2). The association between the exposure
to inappropriate medications and the risk of falls was eval-
uated by computing risk ratios (RR) and their 95% confi-
dence intervals (95% CI) using Cox regression models,
except for comparing use of inappropriate medication in
never, occasional and regular users. Indeed, for the latter
comparison, we did not know whether longitudinal
change in medication use, if any, had occurred before or
after the fall. We therefore assessed the association by
computing odds ratios and their 95% CI from logistic
regression models. The following covariables were
entered in the logistic regression models: age, gender,
study centre, body mass index, diurnal drowsiness,
depressive symptoms, cognitive functioning, impaired
mobility and number of drugs used (excluding inappro-
priate medications). Further adjustment on use of other
inappropriate medications (when examining a given
class) was also performed. Interactions between inappro-
priate medication use and other variables were evaluated
by testing the statistical significance (p < .05) of the inter-
action terms.
All statistical analyses were performed using SAS statistical
software, release 9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Characteristics of the study population
The baseline characteristics of the study population are
shown in Table 2. The 6343 participants had a mean age
of 73.7 years (SD: 5.3) and 59% were women. During the
four years of follow-up, 42.1% of subjects had fallen at
least once and 21.8% had fallen 2 times or more. The inci-
dence of falls increased with age and was higher in women
than in men. It was significantly increased in subjects with
depressive symptoms, impaired mobility, and diurnal
drowsiness. Consumption of 5 or more drugs (excluding
inappropriate drugs) was also a risk factor of falls. Further
analysis showed that, for most characteristics, subjects
who did not report any fall did not differ significantly
from those having fallen only one time, while the latter
group differed from subjects who reported two falls or
more. In the following analyses, the 'No fall' and 'Only
one fall' groups were therefore put together.
About one-third (31.6%) of the 3C study participants
reported using at least one inappropriate medication at
study entry; only 8% used two or more inappropriate
medications. The overall proportion of users was signifi-
cantly associated with the occurrence of falls during fol-
low-up (Table 2). Cerebral vasodilators were the most
frequently reported item (16.3%); the proportion of inap-
propriate medication users was 19.5% when this item was
excluded. Other criteria were reported by less than 5% of
the participants, except long-acting benzodiazepines
(7.8%) and inappropriate medication with anticholiner-
gic properties (5.0%). Inappropriate psychotropic drugs
other than long-acting benzodiazepines were consumed
by 2.1% of the participants. In addition, short- or interme-
diate-acting benzodiazepines were used by 12.2% of par-
ticipants.
Association between baseline use of inappropriate 
medication during the 4 years and risk of falls
The association between baseline use of at least one inap-
propriate medication (including or not including cerebral
vasodilators) and risk of falls did not remain significant in
fully adjusted Cox regression models (Table 3); there was
neither any increased risk of falls in participants using two
or more inappropriate drugs (adjusted RR = 1.14 [0.95–
1.37]). Analyses focusing on specific criteria showed that
users of long-acting benzodiazepines had a significantly
increased risk of falling two times or more during follow-
up. The risk of falls was also slightly increased, but not sig-
nificantly, in users of other psychotropic drugs inappro-BMC Geriatrics 2009, 9:30 http://www.biomedcentral.com/1471-2318/9/30
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priate for elderly and in users of inappropriate medication
with anticholinergic properties. Subjects using short- or
intermediate-acting benzodiazepines were not at
increased risk of falls. Further adjustment for use of other
inappropriate medications did not change these results.
Assessment exposure based on both baseline and follow-
up data showed that 53.7% of participants did not report
any inappropriate medication use at any of the three
examinations, 17.1% reported inappropriate medication
at one examination only (occasional users) and 29.2% at
two or three examinations (regular users). The risk of falls
was significantly increased in regular and/or occasional
users of at least one inappropriate medication (full list or
excluding cerebral vasodilators) (Table 4). Both occa-
sional and regular users of long-acting benzodiazepines
were at higher risk of falls than never users. For inappro-
priate psychotropics or medication with anticholinergic
properties, odds ratios were significantly increased in reg-
ular users only. In contrast, neither occasional use nor reg-
ular use of short- or intermediate-acting benzodiazepines
were associated with falls.
Table 2: Number of Falls during the 4-year follow-up according to the Baseline Characteristics of the Study Population
Variable n (%) No fall (n = 3670) One fall (n = 1291) ≥ 2 falls
(n = 1382)
crude p-value
Women 1922 (52) 833 (65) 987 (71) <.001
Age (years)
<75 2364 (64) 733 (57) 707 (51) <.001
75–79 886 (24) 364 (28) 419 (30)
≥80 420 (12) 194 (15) 256 (19)
Living alone 1107 (30) 494 (38) 574 (41) <.001
Years of schooling
≤5 1204 (33) 420 (33) 474 (34) .86
6–9 1086 (30) 378 (29) 400 (29)
10–12 479 (13) 183 (14) 185 (14)
≥13 901 (24) 308 (24) 322 (23)
Body Mass Index
<25 1701 (46) 641 (50) 648 (48) .09
25–29 1489 (41) 478 (37) 524 (38)
≥30 464 (13) 166 (13) 196 (14)
Depressive symptoms* 369 (10) 176 (14) 201 (15) <.001
MMSE ≥ 28† 2117 (58) 748 (58) 762 (55) .24
Impaired mobility‡ 1351 (37) 579 (46) 724 (53) <.001
Diurnal drowsiness 554 (16) 206 (17) 259 (21) .001
Number of drugs used ≥ 5 § 1140 (31) 459 (36) 573 (41) <.001
At least one inappropriate medication 1092 (30) 408 (32) 504 (36) <.001
* Centre for Epidemiological Studies-Depression scale: women scoring over 22 and men scoring over 16 were considered to have depressive 
symptoms.
† Mini Mental State Examination score.
‡ Participants were classified as having impaired mobility if they were dependant for at least one activity of the Rosow and Breslau scale.
§Inappropriate medications excluded
Table 3: Association between Inappropriate Medication Use and Risk of Fall
≤ 1 fall ≥ 2 falls
Medication n (%) (N = 4961) (N = 1382) RR (95% CI) crude P-value RR (95% CI)* P-value*
Inappropriate medication, full list 1500 (30.2) 504 (36.5)
Inappropriate medication, excluding cerebral 
vasodilators
924 (18.6) 315 (22.8) 1.27 (1.12–1.43) <.001 1.05 (0.92–1.20) .47
Long-acting benzodiazepines 351 (7.1) 144 (10.4) 1.46 (1.23–1.74) <.001 1.20 (1.00–1.43) .048
Inappropriate psychotropic drugs 108 (2.2) 47 (3.4) 1.60 (1.20–2.14) .002 1.31 (0.97–1.76) .08
Inappropriate medication with anticholinergic 
properties
223 (4.5) 92 (6.7) 1.50 (1.21–1.85) <.001 1.18 (0.96–1.47) .13
Short- or intermediate-half-life benzodiazepines 568 (11.5) 206 (14.9) 1.31 (1.13–1.51) <.001 0.99 (0.85–1.16) .89
* Adjusted for age, sex, study centre, body mass index, diurnal drowsiness, number of drugs (excluding inappropriate medication), cognitive 
functioning, depressive symptoms and impaired mobility.BMC Geriatrics 2009, 9:30 http://www.biomedcentral.com/1471-2318/9/30
Page 6 of 10
(page number not for citation purposes)
Data from the national healthcare insurance plan were
obtained for 53% of the study population. Analysis
focused on benzodiazepines. Over a 36-month period
(2001–2003), 25.1% of the 3357 subjects bought at least
one box of long-acting benzodiazepines and 34.5% at
least one box of short- or intermediate-acting benzodi-
azepines. As shown on Figure 1, among the 843 long-act-
ing benzodiazepines users, 35% bought only one box
between 2001 and 2003, 50% less than two boxes, 20%
more than 13 and 10% more than 22 boxes (last decile).
Analysis did not show any dose-effect relation between
the exposure to long-acting benzodiazepines, measured
by the number of boxes, and the risk of falls. The risk of
falls was only increased, but not significantly, in the 10%
of the study population with the highest consumption (>
22 boxes) (adjusted OR = 1.35 [0.78–2.33]). Analysis
detected a significant interaction between the level of
exposure to long-acting benzodiazepines and the MMSE
score (interaction: p = .02). Among subjects with lower
MMSE score (< 28), those with the highest benzodi-
azepine consumption (> 22 boxes) had a significantly
increased risk of falls (adjusted OR = 2.20 [1.07–4.51], p
= .03), while no association between level of exposure and
falls was found in participants with higher MMSE score.
Among users of short- or intermediate-acting benzodi-
azepines, there was no increased risk of falls, whatever the
level of exposure to these medications.
Discussion
In this large community-based study, we found that use of
inappropriate medications increased the risk of falls in
elderly people. Consumption of long-acting benzodi-
azepines was responsible for the main part of this
increase. But regular exposure to inappropriate psycho-
tropic drugs or to inappropriate medication with anti-
cholinergic properties was also associated with an
increased risk of falling. Repeated assessments of medica-
tion use did not bring evidence for a dose-risk relation
between the level or the duration of the exposure to inap-
propriate medications and the risk of falls. There was no
association between use of short- or intermediate-acting
benzodiazepines and occurrence of falls.
Overall, our results were consistent with those of previous
studies about the relation between psychotropic medica-
tion and falls in older people [33-36]. However, previous
studies, did not categorize psychotropic medications as
appropriate or not appropriate for elderly and most of
them did not differentiate benzodiazepines from other
psychotropics. A few studies compared the risk of falls in
long-acting and short- or intermediate-acting benzodi-
Table 4: Risk of Fall in Occasional and Regular Users of Inappropriate Medication compared to Never Users
≤ 1 fall ≥ 2 falls
Medication n (%) (N = 4961) (N = 1382) OR (95% CI) crude P-Value OR (95% CI)*† P-Value†
Inappropriate medication full list
Occasional user‡ 809 (16) 277 (20) 1.48 (1.26–1.74) <.001 1.23 (1.04–1.45) .016
Regular user § 1389 (28) 465 (34) 1.45 (1.26–1.66) <.001 1.08 (0.94–1.25) .29
Inappropriate medication without 
cerebral vasodilators
Occasional user 704 (14) 239 (17) 1.38 (1.17–1.63) <.001 1.22 (1.02–1.45) .030
Regular user 826 (17) 300 (22) 1.48 (1.27–1.72) <.001 1.19 (1.00–1.41) .049
Long-acting benzodiazepines
Occasional user 286 (9) 117 (13) 1.58 (1.26–1.98) <.001 1.40 (1.10–1.79) .006
Regular user 316 (9) 135 (15) 1.65 (1.33–2.04) <.001 1.41 (1.12–1.79) .004
Inappropriate psychotropic drugs
Occasional user 102 (2) 37 (3) 1.33 (0.91–1.95) .14 1.17 (0.74–1.83) .50
Regular user 74 (1) 39 (3) 1.93 (1.30–2.86) .001 1.74 (1.14–2.66) .010
Inappropriate medication with 
anticholinergic properties
Occasional user 264 (5) 91 (7) 1.29 (1.01–1.65) .042 1.21 (0.93–1.58) .15
Regular user 172 (3) 84 (6) 1.83 (1.40–2.40) <.001 1.57 (1.18–2.10) .002
Short- or intermediate-half-life 
benzodiazepines
Occasional user 429 (9) 151 (11) 1.34 (1.10–1.63) .004 1.20 (0.96–1.49) .11
Regular user 441 (9) 153 (11) 1.32 (1.08–1.60) .006 1.05 (0.83–1.32) .69
* Reference group: Never user of inappropriate medication
‡ Occasional user: exposure at only one of the 3 examinations (baseline and 2 follow-up)
§Regular user: exposure at two or three examinations
† Adjusted for age, sex, study centre, Body Mass Index, diurnal drowsiness, number of drugs (excluding IM), cognitive functioning, depressive 
symptoms and impaired mobility.BMC Geriatrics 2009, 9:30 http://www.biomedcentral.com/1471-2318/9/30
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azepines users. Overall, unlike our study, they found that
the risk of falls was independent of the half-life of the drug
[37,38]. Tamblyn et al [39] found an association between
falls and some specific benzodiazepines, but it was inde-
pendent from their half-life.
The design of our multi-site study was well-suited to the
exploration of the relation between drug use and falls,
being a large general population-based cohort, with a
high follow-up rate (92% at 4-year follow-up). Data relat-
ing to classical confounders were available and additional
potential confounders, such as cognitive status, depressive
symptoms, or diurnal drowsiness were assessed and taken
into account in the statistical analysis. Drug consumption
was assessed carefully. Compared with previous studies,
one strength of the present study was the availability of
measures allowing us to investigate the impact of pro-
longed and/or elevated exposure to inappropriate medica-
tion on the risk of falls. Lastly, we used recognized criteria
for selecting medications that are considered as poten-
tially inappropriate for elderly.
Some limitations of our study deserve, however, to be
mentioned. Dosage and indication for prescription were
not available. The precise date of falls was not collected.
Data about some risk factors of falls, as visual acuity, were
not available. Although our study population was quite
large and the overall prevalence of inappropriate medica-
tion use was high (32%), [40-42] numbers were too small
for estimating the risk of falls for specific drug classes,
except for long-acting benzodiazepines. Another limita-
tion which is common to all studies is that self-report of
current drug use, as well as data on drug delivery from the
health care insurance plan are imperfect measurements of
actual drug consumption. Finally, our results may be con-
servative because subjects, whose data on falls were not
available, consumed more inappropriate medication than
the study population.
Most of the drugs potentially inappropriate for the elderly
have known side-effects that can contribute to the risk of
falling: drowsiness, decreased postural reflexes, extra-
pyramidal symptoms, drugging and myorelaxant effect
[43,44]. Age-related changes in drug metabolism and
polypharmacy can increase the frequency and severity of
these side effects, which in turn can increase the risk of
falls. In the 3C study participants, the risk of falling asso-
ciated with the use of inappropriate medication, although
statistically significant, was moderate. We did not find any
high-risk group that could be the target of possible inter-
ventions. However, a small-sized controlled intervention
[45] in persons aged 65 years and over has shown a signif-
icant 66% decrease in the risk of falling after psychotropic
medication withdrawal. Another argument in favour of
Distribution of long-acting benzodiazepines users (N = 843) according to the number of boxes bought between 2001 and 2003 Figure 1
Distribution of long-acting benzodiazepines users (N = 843) according to the number of boxes bought between 
2001 and 2003.
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such interventions is that a given drug can be associated
with different health events. Intervention efficacy should
not therefore be evaluated on a single end-point.
Our study showed that the risk of fall was moderately
increased in elderly users of inappropriate psychotropics
(long-acting benzodiazepines or others) compared to non
users. However, under the hypothesis of a causal relation-
ship, the number of falls attributable to the use of inap-
propriate drugs depends on the exposure prevalence. In
countries with a high consumption of psychotropics, an
important number of falls could be attributable to inap-
propriate use of psychotropics in elderly. Among Euro-
pean countries, France has a high consumption of
psychotropic drugs, with about 50% of subjects over 70
years consuming psychotropics [46]. In a French elderly
community-dwelling population, 31% subjects reported
use of at least one benzodiazepine [47]. In Canada, 22.5%
of elderly were prescribed benzodiazepines in 1998 [48].
Our results on the relation between the duration and/or
intensity of the exposure to inappropriate medications
and the risk of falls are complex. Overall, regular and occa-
sional users of inappropriate medications had similar risk
of falling. In long-acting benzodiazepine users, analysis
did not show significant linear relation (nor even any
trend) between the number of boxes bought over a 3-year
period and the risk of falls, which was increased only in
those who bought more than 22 boxes (last decile of the
distribution). There are several non exclusive explanations
for the absence of a dose-risk relationship. A first possible
explanation is measurement errors. Available measure-
ments (repeated self-reports of current use and data from
the national healthcare insurance plan) are only surrogate
markers of the biological exposure, which depends on
actual drug consumption. Another explanation is a selec-
tion process. Given that persons experiencing drug side-
effects are more likely to stop their treatment than those
without any tolerance problems, it would follow that
long-term users of inappropriate medication could be at
lower risk of undesirable events. Another, and related,
explanation could be that medication side-effects may be
more pronounced at the beginning of the treatment than
after some weeks of use. Under this hypothesis, the
instantaneous risk of fall decreases when the treatment
duration increases. In line with this explanation, a study
[49] showed that the association between benzodiazepine
use and falls was stronger within the 15 days following the
treatment initiation than later on.
Conclusion
Data from the 3C study showed that use of inappropriate
psychotropic drugs, and particularly of long-acting benzo-
diazepines, was associated with an increased risk of falling
in persons aged 65 years and over. Our study showed that
short- or intermediate-acting benzodiazepines did not
increase the risk of falls and, as recommended, they
should be preferred to long-acting benzodiazepines in
elderly patients.
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